Aerocrine enters distribution agreement with Phadia in France

Aerocrine enters distribution agreement with Phadia in France

SOLNA - 20 December, 2007 - Aerocrine AB (OMX Nordic Exchange: AERO) announces
that the company has entered into a distribution agreement with Phadia France.

As of 1 January 2008, Aerocrine has granted Phadia the right to market and sell
NIOX MINO® on the French market. Phadia, a world-leader within allergy
diagnostics, already sells Aerocrine products 
in Spain. 

In France about 4 million people have diagnosed asthma and the prevalence of
asthma like symptoms is even higher, about 15%.

“Phadia has an established market position in France in addition to good
knowledge of our products. We look forward to working together with Phadia to
launch Aerocrine's products in France,” says Paul de Potocki, CEO of Aerocrine.

“Through Phadia's distribution of NIOX MINO in Spain, we have established a
strong relationship with Aerocrine and have developed a good understanding of
patient benefits from the company's products. We are pleased to be entrusted
with selling Aerocrine's products in France as well,” says Magnus Lundberg, CEO
of Phadia. 

For more information, contact

Paul de Potocki, CEO Aerocrine, telephone: +46 8 629 07 82

Santiago Pulido, Senior Vice President Phadia, telephone: +34 639 82 01 26

Aerocrine discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 10:00 AM on December 20, 2007.

About Aerocrine
Aerocrine AB is a clinically based medical technology corporation dedicated to
improved asthma management and care. Aerocrine was listed on the Stockholm Stock
Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide
basis and is also marketing NIOX MINO®, representing a new generation of
hand-held devices, in Europe. Both products are tailored for rapid, non-invasive
control of the inflammatory status in the airways and may play a critical role
for optimized asthma care and disease control. Aerocrine is located in Sweden
with wholly owned subsidiaries in the US, UK and Germany.

About Phadia 
Phadia develops, manufactures and markets complete blood test systems to support
the clinical diagnosis and monitoring of allergy, asthma and autoimmune
diseases. More than 3,000 laboratories in 60 countries use the company's
products. Supplying seven out of ten allergy laboratory tests worldwide, Phadia
has remained the world leader in its field for more than 25 years. Phadia's
ImmunoCAP symptom profiles provide allergists, pediatricians and primary care
physicians with precise, quantitative measurements of specific IgE levels,
supporting the prognosis, diagnosis and follow-up of allergic patients.